Article
SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes - Nature Reviews Cardiology
Rating:
0.0
Views:
51
Likes:
1
Library:
1
Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular events by 20% compared with placebo in patients who are overweight or obese and with pre-existing cardiovascular disease but without diabetes mellitus, according to findings from the SELECT trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value